Wanis Kerollos Nashat, Emmerton-Coughlin Heather M, Coughlin Shaun, Foley Norine, Vinden Christopher
1 Department of Surgery, Western University, London Health Sciences Centre, London, Canada 2 Department of Physical Medicine & Rehabilitation, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Dis Colon Rectum. 2017 Apr;60(4):446-455. doi: 10.1097/DCR.0000000000000792.
Hemorrhoidectomy is associated with significant postoperative pain. Oral metronidazole has been recommended as an adjunct to improve posthemorrhoidectomy analgesia.
This study aimed to evaluate the impact of oral metronidazole on patient-reported pain following hemorrhoidectomy.
We conducted a systematic search in the MEDLINE, EMBASE, ISI Web of Science, and Cochrane Central Register of Controlled Trials databases.
Randomized controlled trials examining adults who underwent surgical hemorrhoidectomy were included. Participants in an active intervention group received oral metronidazole postoperatively, and those in a control group received placebo or usual care. Postoperative pain was assessed for at least 3 days postoperatively.
A random-effects model was used.
The primary outcome was pain during the first 2 postoperative weeks, measured on a visual analogue scale. The secondary outcome was time to return to normal activities.
Patients who received oral metronidazole had significantly lower reported pain scores on postoperative day 1 (standardized mean difference, -0.87 ± 0.44; 95% CI, -1.73 to -0.015; p = 0.046; n = 4) and day 4 (standardized mean difference, -1.43 ± 0.71; 95% CI, -2.83 to -0.037; p = 0.044; n = 3). Metronidazole use was associated with a significantly shorter time to return to normal activities (standardized mean difference, -0.76 ± 0.34; 95% CI, -1.43 to -0.088, p = 0.027). The improvements disappeared in a sensitivity analysis excluding the largest trial with a high risk of bias, and no significance was observed during the remaining postoperative days.
The meta-analysis was limited by lack of double blinding, absence of a placebo, and unclear or high risk of bias in a proportion of the included trials.
Although a favorable adverse effect profile supports consideration of oral metronidazole to reduce posthemorrhoidectomy pain, pooled analysis reveals inconsistent results with no pain reduction on most postoperative days. The current recommendation for routine prescription of oral metronidazole should be reevaluated in the absence of additional well-designed trials.
痔切除术与显著的术后疼痛相关。口服甲硝唑已被推荐作为改善痔切除术后镇痛的辅助药物。
本研究旨在评估口服甲硝唑对痔切除术后患者报告的疼痛的影响。
我们在MEDLINE、EMBASE、ISI科学网和Cochrane对照试验中央注册库数据库中进行了系统检索。
纳入了对接受手术痔切除术的成年人进行检查的随机对照试验。积极干预组的参与者术后接受口服甲硝唑,对照组的参与者接受安慰剂或常规护理。术后至少3天评估术后疼痛。
采用随机效应模型。
主要结局是术后前2周的疼痛,采用视觉模拟量表测量。次要结局是恢复正常活动的时间。
接受口服甲硝唑的患者在术后第1天(标准化均数差,-0.87±0.44;95%CI,-1.73至-0.015;p=0.046;n=4)和第4天(标准化均数差,-1.43±0.71;95%CI,-2.83至-0.037;p=0.044;n=3)报告的疼痛评分显著更低。使用甲硝唑与恢复正常活动的时间显著缩短相关(标准化均数差,-0.76±0.34;95%CI,-1.43至-0.088,p=0.027)。在排除偏倚风险高的最大试验的敏感性分析中,这些改善消失了,并且在其余术后天数未观察到显著性。
荟萃分析受到缺乏双盲、无安慰剂以及部分纳入试验中偏倚不明确或风险高的限制。
尽管有利的不良反应特征支持考虑口服甲硝唑以减轻痔切除术后疼痛,但汇总分析显示结果不一致,在大多数术后天数疼痛并未减轻。在没有额外精心设计试验的情况下,目前关于口服甲硝唑常规处方的建议应重新评估。